RJA
CLDX icon

Raymond James & Associates’s Celldex Therapeutics CLDX Stock Holding History

Raymond James & Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,416
Closed -$4K – 3635
2018
Q4 		$4K Hold
1,416
– – ﹤0.01% 3494
2018
Q3 		$10K Sell
1,416
-3
-0.2% -$21 ﹤0.01% 3579
2018
Q2 		$11K Sell
1,419
-179
-11% -$2.39K ﹤0.01% 3521
2018
Q1 		$56K Hold
1,598
– – ﹤0.01% 3311
2017
Q4 		$68K Buy
1,598
+185
+13% +$7.92K ﹤0.01% 3255
2017
Q3 		$61K Sell
1,413
-9
-0.6% -$337 ﹤0.01% 3225
2017
Q2 		$53K Buy
1,422
+637
+81% +$28.2K ﹤0.01% 3179
2017
Q1 		$43K Buy
785
+53
+7% +$2.76K ﹤0.01% 3154
2016
Q4 		$39K Sell
732
-33
-4% -$1.88K ﹤0.01% 3105
2016
Q3 		$46K Buy
+765
New +$47.6K ﹤0.01% 3086
2015
Q3 		– Sell
-775
Closed -$293K – 2283
2015
Q2 		$293K Sell
775
-130
-14% -$51.6K ﹤0.01% 2289
2015
Q1 		$378K Buy
+905
New +$324K ﹤0.01% 2144

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Raymond James & Associates's CLDX Position: Q1 2019 in Review

Raymond James & Associates sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 1,416 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in CLDX in Q1 2015 and held it in 12 quarters. The position peaked at $378K in Q1 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Raymond James & Associates reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Raymond James & Associates sold 1,416 Celldex Therapeutics shares in Q1 2019, an estimated $4K.
  • Raymond James & Associates first reported a position in Celldex Therapeutics in Q1 2015 and held it in 12 quarters.
  • Raymond James & Associates's Celldex Therapeutics position peaked at $378K in Q1 2015.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Raymond James & Associates's 13F filing for Q1 2019, filed 6 May 2019.